ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1
1. NAME OF THE MEDICINAL PRODUCT

Pedea 5 mg/ml solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of the solution contains 5 mg ibuprofen.

Each ampoule of 2 ml contains 10 mg ibuprofen.

Excipients: each ml contains 7.5 mg of sodium.

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection.

Clear, colourless to slightly yellow solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less
than 34 weeks of gestational age.

4.2 Posology and method of administration

Treatment with Pedea should only be carried out in a neonatal intensive care unit under the
supervision of an experienced neonatologist.

Posology
A course of therapy is defined as three intravenous injections of Pedea given at 24-hour intervals. The
first injection should be given after the first 6 hours of life.
The ibuprofen dose is adjusted to the body weight as follows:
- 1st injection: 10 mg/kg,
- 2nd and 3rd injections: 5 mg/kg.

If anuria or manifest oliguria occurs after the first or second dose, the next dose should be withheld
until urine output returns to normal levels.
If the ductus arteriosus does not close 48 hours after the last injection or if it re-opens, a second course
of 3 doses, as above, may be given.
If the condition is unchanged after the second course of therapy, surgery of the patent ductus
arteriosus may then be necessary.

Method of administration
For intravenous use only.
Pedea should be administered as a short infusion over 15 minutes, preferably undiluted. If necessary,
the injection volume may be adjusted with either sodium chloride 9 mg/ml (0.9%) solution for
injection or glucose 50 mg/ml (5%) solution for injection. Any unused portion of the solution should
be discarded.
The total volume of solution injected should take into account the total daily fluid volume
administered.

2
4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients;

- Life-threatening infection;
- Active bleeding, especially intracranial or gastrointestinal haemorrhage;
- Thrombocytopenia or coagulation defects;
- Significant impairment of renal function;
- Congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory
pulmonary or systemic blood flow (e.g. pulmonary atresia, severe tetralogy of Fallot, severe
coarctation of the aorta);
- Known or suspected necrotising enterocolitis;

4.4 Special warnings and precautions for use

Before administration of Pedea an adequate echocardiographic examination should be performed in

order to detect a haemodynamically significant patent ductus arteriosus and to exclude pulmonary
hypertension and ductal-dependent congenital heart disease.

Since prophylactic use in the first 3 days of life (starting within 6 hours of birth) in preterm newborn
infants less than 28 weeks of gestational age was associated with increased pulmonary and renal
adverse events, Pedea should not be used prophylactically at any gestational age (see sections 4.8 and
5.1). In particular, severe hypoxemia with pulmonary hypertension was reported in 3 infants within
one hour of the first infusion and was reversed within 30 min after start of inhaled nitric oxide therapy.
If hypoxaemia occurs during or following Pedea infusion, close attention should be paid to pulmonary
pressure.

Since ibuprofen was shown in vitro to displace bilirubin from its binding site to albumin, the risk of
bilirubin encephalopathy in premature newborn infants may be increased (see section 5.2). Therefore,
ibuprofen should not be used in infants with marked elevated bilirubin concentration.

As a non-steroidal anti-inflammatory drug (NSAID), ibuprofen may mask the usual signs and
symptoms of infection. Pedea must therefore be used cautiously in the presence of an infection (see
also section 4.3).

Pedea should be administered carefully to avoid extravasation and potential resultant irritation to
tissues.

As ibuprofen may inhibit platelet aggregation, premature neonates should be monitored for signs of
bleeding.

As ibuprofen may decrease the clearance of aminoglycosides, strict surveillance of their serum levels
is recommended during co-administration with ibuprofen.

Careful monitoring of both renal and gastrointestinal function is recommended.

In preterm newborn infants less than 27 weeks of gestational age, the closure rate of the ductus
arteriosus (33 to 50%) was shown to be low at the recommended dose regimen (see section 5.1).

This medicinal product contains less than 1 mmol sodium (15 mg) per 2 ml, i.e. essentially ‘sodium-
free’.

4.5 Interaction with other medicinal products and other forms of interaction

The concomitant use of Pedea with the following medicinal products is not recommended:
- diuretics: ibuprofen may reduce the effect of diuretics; diuretics can increase the risk of
nephrotoxicity of NSAIDs in dehydrated patients.

3
- anticoagulants: ibuprofen may increase the effect of anticoagulants and enhance the risk of
bleeding.
- corticosteroids: ibuprofen may increase the risk of gastrointestinal bleeding.
- nitric oxide: since both medicinal products inhibit platelet function, their combination may in
theory increase the risk of bleeding.
- other NSAIDs: the concomitant use of more than one NSAID should be avoided because of the
increased risk of adverse reactions.
- aminoglycosides: since ibuprofen may decrease the clearance of aminoglycosides, their co-
administration may increase the risk of nephrotoxicity and ototoxicity (see section 4.4).

4.6 Pregnancy and lactation

Not relevant

4.7 Effects on ability to drive and use machines

Not relevant

4.8 Undesirable effects

Data are currently available on approximately 1,000 preterm newborn from both the literature
concerning ibuprofen and clinical trials with Pedea. Causality of adverse events reported in the
preterm newborn is difficult to assess since they may be related to the haemodynamic consequences of
the patent ductus arteriosus as well as to direct effects of ibuprofen.

Reported adverse reactions are listed below, by system organ class and by frequency. Frequencies are
defined as: very common (≥ 1/10), common (≥1/100, <1/10) and uncommon (≥1/1,000, <1/100).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Blood and lymphatic system disorders Very common: Thrombocytopenia, Neutropenia

Nervous system disorders Common: Intraventricular haemorrhage,
Periventricular leukomalacia
Respiratory, thoracic and mediastinal Very common: Bronchopulmonary dysplasia*
disorders Common: Pulmonary haemorrhage
Uncommon: Hypoxemia*
Gastrointestinal disorders Common: Necrotizing enterocolitis, Intestinal
perforation
Uncommon: Gastrointestinal haemorrhage
Renal and urinary disorders Common: Oliguria, Fluid retention, Haematuria
Uncommon: Acute renal failure
Investigations Very Common: Blood creatinine increased, Blood
sodium decreased
* see below

In a clinical curative trial involving 175 preterm newborn infants less than 35 weeks of gestational
age, the incidence of bronchopulmonary dysplasia at 36 weeks post-conceptional age was 13/81 (16%)
for indomethacin versus 23/94 (24%) for ibuprofen.

In a clinical trial where Pedea was administered prophylactically during the first 6 hours of life, severe
hypoxemia with pulmonary hypertension was reported in 3 newborn infants less than 28 weeks of
gestational age. This occurred within one hour of the first infusion and was reversed within 30 minutes
after the inhalation of nitric oxide. There have also been post-marketing reports of pulmonary
hypertension where Pedea was administered to premature neonates in the therapeutic setting.

4
4.9 Overdose

No case of overdose has been reported with intravenous ibuprofen in preterm newborn infants.

However, overdose has been described in infants and children administered oral ibuprofen: CNS
depression, seizures, gastrointestinal disturbances, bradycardia, hypotension, apnoea, abnormal renal
function, haematuria have been observed.
Massive overdose (up to more than 1000 mg/kg) has been reported to induce coma, metabolic
acidosis, and transient renal failure. All patients recovered with conventional treatment. Only one
recorded death has been published: after an overdose of 469 mg/kg, a 16-month old child developed
an apnoeic episode with seizures and a fatal aspiration pneumonia.

The management of ibuprofen overdose is primarily supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other cardiac preparations, ATC code: C01 EB16

Ibuprofen is a NSAID that possesses anti-inflammatory, analgesic and antipyretic activity. Ibuprofen
is a racemic mixture of S(+) and R(-) enantiomers. In vivo and in vitro studies indicate that the S(+)
isomer is responsible for the clinical activity. Ibuprofen is a non selective inhibitor of cyclo-
oxygenase, leading to reduced synthesis of prostaglandins.
Since prostaglandins are involved in the persistence of the ductus arteriosus after birth, this effect is
believed to be the main mechanism of action of ibuprofen in this indication.

In a dose-response study of Pedea in 40 preterm newborn infants, the ductus arteriosus closure rate
associated to the 10-5-5 mg/kg dose regimen was 75% (6/8) in neonates of 27-29 weeks’ gestation and
33% (2/6) in neonates of 24-26 weeks’ gestation.

Prophylactic use of Pedea in the first 3 days of life (starting within 6 hours of birth) in preterm
newborn infants less than 28 weeks of gestational age was associated with increased incidence of renal
failure and pulmonary adverse events including hypoxia, pulmonary hypertension, pulmonary
haemorrhage, as compared to curative use. Conversely, a lower incidence of neonatal grade III-IV
intraventricular haemorrhage and of surgical ligation was associated with prophylactic use of Pedea.

5.2 Pharmacokinetic properties

Distribution
Although a great variability is observed in the premature population, peak plasma concentrations are
measured around 35-40 mg/l after the initial loading dose of 10 mg/kg as well as after the last
maintenance dose, whatever gestational and postnatal age. Residual concentrations are around 10-
15 mg/l 24 hours after the last dose of 5 mg/kg.
Plasma concentrations of the S-enantiomer are much higher than those of the R-enantiomer, which
reflects a rapid chiral inversion of the R- to the S-form in a proportion similar to adults (about 60%).

The apparent volume of distribution is on average 200 ml/kg (62 to 350 according to various studies).
The central volume of distribution may depend on the status of the ductus and decrease as the ductus
closes.

In vitro studies suggest that, similarly to other NSAIDs, ibuprofen is highly bound to plasma albumin,
although this seems to be significantly lower (95 %) compared with adult plasma (99 %). Ibuprofen
competes with bilirubin for albumin binding in newborn infant serum and, as a consequence, the free
fraction of bilirubin may be increased at high ibuprofen concentrations.

5
Elimination
Elimination rate is markedly lower than in older children and adults, with an elimination half-life
estimated at approximately 30 hours (16–43). The clearance of both enantiomers increases with
gestational age, at least in the range of 24 to 28 weeks.

PK-PD relationship
In preterm newborns ibuprofen significantly reduced plasma concentrations of prostaglandins and
their metabolites, particularly PGE2 and 6-keto-PGF-1-alpha. Low levels were sustained up to
72 hours in neonates who received 3 doses of ibuprofen, whereas subsequent re-increases were
observed at 72 hours after only 1 dose of ibuprofen.

5.3 Preclinical safety data

There are no preclinical data considered relevant to clinical safety beyond data included in other
sections of this Summary of Product Characteristics. With the exception of an acute toxicity study, no
further studies have been carried out in juvenile animals with Pedea.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Trometamol,
sodium chloride,
sodium hydroxide (for pH adjustment),
hydrochloric acid 25% (for pH adjustment),
water for injections.

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in
section 6.6.

Pedea solution must not be in contact with any acidic solution such as certain antibiotics or diuretics.
A rinse of the infusion line must be performed between each product administration (see section 6.6).

6.3 Shelf life

4 years.
To avoid any possible microbiological contamination, the product should be used immediately after
first opening.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

2 ml solution in a colourless type 1 glass ampoule.

Pedea is supplied in packs of 4 x 2 ml ampoules.

6.6 Special precautions for disposal and other handling

As for all parenteral products, ampoules of Pedea should be visually inspected for particulate matter
and the integrity of the container prior to use. Ampoules are intended for single use only, any unused
portions must be discarded.

6
Chlorhexidine must not be used to disinfect the neck of the ampoule as it is not compatible with the
Pedea solution. Therefore, for asepsis of the ampoule before use, ethanol 60% or isopropyl alcohol
70% is recommended.
When disinfecting the neck of the ampoule with an antiseptic, to avoid any interaction with the Pedea
solution, the ampoule must be completely dry before it is opened.

The required volume to be given to the infant should be determined according to body weight, and
should be injected intravenously as a short infusion over 15 minutes, preferably undiluted.

Use only sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution to
adjust injection volume.
The total volume of solution injected to preterm infants should take into account the total daily fluid
volume administered. A maximal volume of 80 ml/kg/day on the first day of life should usually be
respected; this should be progressively increased in the following 1-2 weeks (about 20 ml/kg
birthweight/day) up to a maximal volume of 180 ml/kg birthweight/day.

Before and after administration of Pedea, to avoid contact with any acidic solution, rinse the infusion
line over 15 minutes with 1.5 to 2 ml of either sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml
(5%), solution for injection.

After first opening of an ampoule, any unused portions must be discarded.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Orphan Europe SARL

Immeuble “Le Wilson”
70, avenue du Général de Gaulle
F-92800 Puteaux
France

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/284/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29 July 2004

Date of renewal: 29 July 2009

10. DATE OF REVISION OF THE TEXT

Detailed information on this product is available on the web site of the European medicines Agency
(EMEA) http://www.emea.europa.eu

7
 ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH

RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY

AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE

MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT

8
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Orphan Europe SARL

Immeuble “Le Wilson”
70, avenue du Général de Gaulle
F- 92800 Puteaux,
France

or

Orphan Europe SARL

(FR5LYHUParc
3, rue des Peupliers
F-92000 Nanterre
France

The printed package leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING

AUTHORISATION

• Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product
in accordance with the requirements set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83/EC and published on the European
medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND

EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk Management Plan (RMP)

Not applicable.

9
 ANNEX III

LABELLING AND PACKAGE LEAFLET

10
A. LABELLING

11
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON TEXT

1. NAME OF THE MEDICINAL PRODUCT

Pedea 5 mg/ml solution for injection

Ibuprofen

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml contains 5 mg ibuprofen

Each ampoule of 2 ml contains 10 mg ibuprofen

3. LIST OF EXCIPIENTS

Excipients: t rometamol, s odium c hloride, s odium hy droxide, hy drochloric a cid 25 %, w ater f or

injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Solution for injection

4 x 2 ml ampoules

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intravenous use as short infusion

Read the package leaflet before use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT

OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
From a microbiological point of view, the product should be used immediately

9. SPECIAL STORAGE CONDITIONS

12
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS
OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE

After first opening of an ampoule any unused portions must be discarded.

Any unused product or waste material should be disposed of in accordance with local requirements.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Orphan Europe S.A.R.L.,

Immeuble “Le Wilson”
70, avenue du Général de Gaulle
F- 92800 Puteaux
France

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/04/284/001

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

13
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

GLASS AMPOULE LABEL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Pedea 5 mg/ml solution for injection

Ibuprofen
IV use

2. METHOD OF ADMINISTRATION

See leaflet

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

10 mg / 2 ml

6. OTHER

14
B. PACKAGE LEAFLET

15
 PACKAGE LEAFLET: INFORMATION FOR THE USER

Pedea 5mg/ml solution for injection

Ibuprofen

Read all of this leaflet carefully before this medicine is administered to your baby.
- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- This medicine has been prescribed for your baby. Do not pass it on to others. It may harm
them, even if their symptoms are the same as your baby’s.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,
please tell your doctor or your pharmacist.

In this leaflet:
1. What Pedea is and what it is used for
2. Before Pedea is administered to your baby
3. How Pedea is used
4. Possible side effects
5. How to store Pedea
6. Further information

1. WHAT PEDEA IS AND WHAT IT IS USED FOR

While a baby is inside its mother’s womb it does not need to use its lungs. An unborn baby has a blood
vessel called the ductus arteriosus near the heart which allows the baby’s blood to bypass the lungs
and circulate to the rest of the body.
When the baby is born and starts using its lungs the ductus arteriosus normally closes. However, in
some cases this does not happen. The medical term for this condition is ‘patent ductus arteriosus’, i.e.
an open ductus arteriosus. This can cause heart problems in your baby. This condition is much more
frequent in premature newborn than in full-term newborn infants.
Pedea, when given to your baby, can help to close the ductus arteriosus.

The active substance in P edea i s i buprofen. Pedea closes the ductus arteriosus by i nhibiting t he
production of prostaglandin, a na turally oc curring c hemical i n t he body w hich keeps t he ductus
arteriosus open.

2. BEFORE PEDEA IS ADMINISTERED TO YOUR BABY

Pedea will only be given to your baby in a special neonatal intensive care unit by qualified health care
professionals.

Do not use Pedea

- if your baby is allergic (hypersensitive) to ibuprofen or any of the other ingredients of Pedea;
- if your baby has a life-threatening infection which has not been treated;
- if your baby is bleeding, especially if the bleeding is inside the skull or in the intestines;
- if your baby has a decrease of blood cells called platelets (thrombocytopenia) or other problems
with their blood clotting;
- if your baby has kidney problems;
- if y our ba by ha s ot her pr oblems w ith t heir he art w hich r equire t he ductus arteriosus to r emain
open so that adequate circulation of the blood is maintained;
- if your baby has or is suspected to have certain problems with their intestines (a condition called
necrotising enterocolitis);

16
Take special care with Pedea
- Before treatment with Pedea, your baby’s heart will be examined to confirm that the ductus
arteriosus is open.
- Pedea should not be given in the first 6 hours of life.
- If your baby is suspected of having liver disease, signs and symptoms of which include yellowing
of the skin and eyes.
- If your baby is already suffering from an infection that is being treated, the doctor will treat your
baby with Pedea only after careful consideration of your baby’s condition.
- Pedea should be carefully administered to your baby by the healthcare professional, to avoid
damage to the skin and surrounding tissues.
- Ibuprofen may reduce the ability of your baby’s blood to clot. Your baby should therefore be
watched for signs of prolonged bleeding.
- Your baby may develop some bleeding from the intestines and the kidneys. To detect this, your
baby’s stools and urine may be tested to determine if there is any blood present in them.
- Pedea may reduce the amount of urine your baby passes. If this is significant, your baby’s
treatment may be stopped until the volume of urine returns to normal.
- Pedea may be less effective in very premature babies less than 27 weeks of gestational age.

Using other medicines

Please tell your doctor or pharmacist if your baby is taking or has recently taken any other medicines,
including medicines obtained without a prescription.

Certain medicines, if given together with Pedea, may cause side effects. These are detailed below:

- your baby may have problems passing urine and may have been prescribed diuretics. Ibuprofen
may reduce the effect of these medicines.

- your baby may be given anticoagulants (medicine preventing blood clotting). Ibuprofen may
increase the anti-clotting effect of this product.

- your baby may be given nitric oxide to improve blood oxygenation. Ibuprofen may increase the
risk of bleeding.

- your baby may be given corticosteroids to prevent inflammation. Ibuprofen may increase the
risk of bleeding in the stomach and intestines.

- your baby may be given aminosides (one family of antibiotics) to treat infection. Ibuprofen may
increase blood concentrations and thus increase the risk of toxicity on kidney and ear

Important information about some of the ingredients of Pedea

This medicinal product contains less than 1 mmol sodium (15 mg) per 2 ml, i.e. essentially ‘sodium-
free’.

3. HOW PEDEA IS USED

Pedea will only be given to your baby in a special neonatal intensive care unit by qualified healthcare
professional.

A course of therapy is defined as three intravenous injections of Pedea given at 24 hour intervals. The
dose to be administered will be calculated from the weight of your baby. It is 10 mg/kg for the first
administration and 5 mg/kg for the second and the third administrations.

This calculated amount will be given by infusion in a vein over a period of 15 minutes.
If af ter this f irst c ourse o f t reatment, the ductus arteriosus is no t c losed o r r e-opens, y our ba by’s
doctor may decide to give a second course of treatment.

17
If after the second course of treatment, the ductus arteriosus is still not closed, a surgery may then be
proposed.

4. POSSIBLE SIDE EFFECTS

Like al l m edicines, P edea can c ause side e ffects, a lthough n ot ev erybody g ets t hem. H owever, i t i s
difficult t o di stinguish them f rom f requent c omplications oc curring i n p remature babies and
complications due to the disease.

The frequency of possible side effects listed below is defined using the following convention:
very common (affects more than 1 user in 10)
common (affects 1 to 10 users in 100)
uncommon (affects 1 to 10 users in 1,000)
very rare (affects less than 1 user in 10,000)
not known (frequency cannot be estimated from the available data)

Very common:
- Decrease in the number of platelets in the blood (thrombocytopenia),
- Decrease in white blood cells called neutrophils (neutropenia),
- Increase in creatinine level in the blood,
- Decrease in sodium level in the blood,
- Breathing problems (bronchopulmonary dysplasia),

Common:
- Bleeding i nside t he s kull ( intraventricular ha emorrhage) a nd b rain i njury ( periventricular
leukomalacia),
- Bleeding in the lung,
- Perforation of the intestine and injury of intestinal tissue (necrotizing enterocolitis),
- Reduced volume of urine passed, blood in the urine, fluid retention

Uncommon:
- Acute failure of the kidney’s functions
- Bleeding in the intestine
- Below normal oxygen content in the arterial blood (hypoxemia)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please
tell your baby’s doctor or your pharmacist.

5. HOW TO STORE PEDEA

Keep out of reach and sight of children.

Do not use Pedea after the expiry date which is stated on the carton and label after EXP. The expiry
date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

After opening, Pedea should be administered immediately.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to
dispose of medicines no longer required. These measures will help to protect the environment.

18
6. FURTHER INFORMATION

What Pedea contains

- The a ctive substance is ibuprofen. E ach m l co ntains 5 mg i buprofen. E ach 2 m l a mpoule

contains 10 mg ibuprofen.
- The other ingredients are trometamol, sodium chloride, sodium hydroxide (for pH adjustment),
hydrochloric acid 25% (for pH adjustment) and water for injections.

What Pedea looks like and contents of the pack

Pedea 5mg/ml solution for injection is a clear, colourless to slightly yellow solution.
Pedea 5mg/ml solution for injection is supplied in cartons of four 2 ml ampoules.

Marketing Authorisation Holder

Orphan Europe SARL
Immeuble “Le Wilson”
70, avenue du Général de Gaulle
F- 92800 Puteaux
France

Manufacturer
Orphan Europe SARL
Immeuble “Le Wilson”
70, avenue du Général de Gaulle
F-92800 Puteaux
France

or

Orphan Europe SARL

Eco River Parc
30, rue des Peupliers
F-92000 Nanterre
France

For an y i nformation ab out t his m edicine, p lease c ontact t he l ocal r epresentative o f t he M arketing
Authorisation Holder.

Belgique/België/Belgien Lietuva
Orphan Europe Benelux Orphan Europe AB
Koning Albert I laan 48 bus 3 Isafjordsgatan 30C, plan 3
BE-1780 Wemmel (Brussels) S-164 40 Kista
Tél/Tel: +32 2 46101 36 Švedija
Tel: + 46 8 545 80 230

България Luxembourg/Luxemburg
Orphan Europe (Germany) GmbH Orphan Europe Benelux
Eberhard-Finckh-Straße 55 Koning Albert I laan 48 bus 3
D-89075 Ulm BE-1780 Wemmel(Brussels)
Германия Belgique/Belgien
Tel: +49 731 140 554 0 Tél/Tel: +32 2 46101 36

19
Česká republika Magyarország
Orphan Europe (Germany) GmbH Orphan Europe (Germany) GmbH
Eberhard-Finckh-Straße 55 Eberhard-Finckh-Straße 55
D-89075 Ulm D-89075 Ulm
Německo Németország
Tel: +49 731 140 554 0 Tel: +49 731 140 554 0

Danmark Malta
Orphan Europe AB Orphan Europe SARL
Isafjordsgatan 30C, plan 3 Immeuble “Le Wilson”
S-164 40 Kista 70, avenue du Général de Gaulle
Sverige F-92800 Puteaux
Tlf : +46 8 545 80 230 Franza
Tel: +33 1 47 73 64 58

Deutschland Nederland
Orphan Europe (Germany) GmbH Orphan Europe Benelux
Eberhard-Finckh-Straße 55 Koning Albert I Iaan 48 bus 3
D-89075 Ulm BE-1780 Wemmel (Brussels)
Tel: +49 731 140 554 0 België
Tel: +32 2 46101 36

Eesti Norge
Orphan Europe AB Orphan Europe AB
Isafjordsgatan 30C, plan 3 Isafjordsgatan 30C, plan 3
S-164 40 Kista S-164 40 Kista
Rootsi Sverige
Tel: + 46 8 545 80 230 Tlf : +46 8 545 80 230

Ελλάδα Österreich
Orphan Europe SARL Orphan Europe (Germany) GmbH
Immeuble “Le Wilson” Eberhard-Finckh-Straße 55
70, avenue du Général de Gaulle D-89075 Ulm
F-92800 Puteaux Deutschland
Γαλλία Tel: +49 731 140 554 0
Τηλ: +33 1 47 73 64 58

España Polska
Orphan Europe, S.L. Orphan Europe (Germany) GmbH
C/ Isla de la Palma, 37, 2a planta Eberhard-Finckh-Straße 55
E-28700 San Sebastián de los Reyes, Madrid D-89075 Ulm
Tel: + 34 91 659 28 90 Niemcy
Tel: +49 731 140 554 0

France Portugal
Orphan Europe SARL Orphan Europe, S.L.
Immeuble “Le Wilson” C/ Isla de la Palma, 37, 2a planta
70, avenue du Général de Gaulle E-28700 San Sebastián de los Reyes, Madrid
F-92800 Puteaux Espanha
Tél: +33 (0)1 47 73 64 58 Tel: +34 91 659 28 90

20
Hrvatska România
Orphan Europe SARL Orphan Europe (Germany) GmbH
Immeuble “Le Wilson” Eberhard-Finckh-Straße 55
70, avenue du Général de Gaulle D-89075 Ulm
F-92800 Puteaux Germania
Francuska Tel: +49 731 140 554 0
Tél: +33 (0)1 47 73 64 58

Ireland Slovenija
Orphan Europe (UK) Ltd. Orphan Europe (Germany) GmbH
Isis House, 43 Station road Eberhard-Finckh-Straße 55
Henley-on-Thames D-89075 Ulm
Oxfordshire RG9 1AT – UK Nemčija
United Kingdom Tel: +49 731 140 554 0
Tel: +44 1491 414333

Ísland Slovenská republika

Orphan Europe AB Orphan Europe (Germany) GmbH
Isafjordsgatan 30C, plan 3 Eberhard-Finckh-Straße 55
S-164 40 Kista D-89075 Ulm
Svíþjóð Nemecko
Simi:+46 8 545 80 230 Tel: +49 731 140 554 0

Italia Suomi/Finland
Orphan Europe (Italy) Srl Orphan Europe AB
Via Marostica, 1 Isafjordsgatan 30C, plan 3
I-20146 Milano S-164 40 Kista
Tel: +39 02 487 87 173 Sverige
Puh/Tel : +46 8 545 80 230

Κύπρος Sverige
Orphan Europe SARL Orphan Europe AB
Immeuble “Le Wilson” Isafjordsgatan 30C, plan 3
70, avenue du Général de Gaulle S-164 40 Kista
F – 92800 Puteaux Tel : +46 8 545 80 230
Γαλλία
Τηλ : +33 1 47 73 64 58

Latvija United Kingdom

Orphan Europe AB Orphan Europe (UK) Ltd.
Isafjordsgatan 30C, plan 3 Isis House, 43 Station road
S-164 40 Kista Henley-on-Thames
Zviedrija Oxfordshire RG9 1AT - UK
Tel: + 46 8 545 80 230 Tel: +44 (0)1491 414333

This leaflet was last approved in

Detailed information o n this m edicine i s av ailable o n t he E uropean m edicines A gency w ebsite:

http://emea.europa.eu

21
The following information is intended for medical or healthcare professionals only:

As for all parenteral products, ampoules of Pedea should be visually inspected for particulate matter
and the integrity of the container prior to use. Ampoules are intended for single use only, any unused
portions must be discarded.

Posology and method of administration (see also section 3)

For intravenous use only. Treatment with Pedea can only be carried out in a neonatal intensive care
unit under the supervision of an experienced neonatologist.
A course of therapy is defined as three intravenous doses of Pedea given at 24-hour intervals.
The ibuprofen dose is adjusted to the body weight as follows:
- 1st injection: 10 mg/kg,
- 2nd and 3rd injections: 5 mg/kg.

If the ductus arteriosus does not close 48 hours after the last injection or if it re-opens, a second course
of 3 doses, as above, may be given.
If the condition is unchanged after the second course of therapy, surgery of the PDA may then be
necessary.
If anuria or manifest oliguria occurs after the first or second dose, the next dose should be withheld
until urine output returns to normal levels.

Method of administration:
Pedea should be administered as a short infusion over 15 minutes, preferably undiluted. To facilitate
the administration an infusion pump may be used.
If necessary, the injection volume may be adjusted with either sodium chloride 9 mg/ml (0.9%)
solution for injection or glucose 50 mg/ml (5%) solution for injection. Any unused portion of the
solution should be discarded.
The total volume of solution injected to preterm infants should take into account the total daily fluid
volume administered. A maximal volume of 80 ml/kg/day on the first day of life should usually be
respected; this should be progressively increased in the following 1-2 weeks (about 20 ml/kg
birthweight/day) up to a maximal volume of 180 ml/kg birthweight/day.

Incompatibilities

Chlorhexidine must not be used to disinfect the neck of the ampoule as it is not compatible with the
Pedea solution. Therefore, for asepsis of the ampoule before use, ethanol 60% or isopropyl alcohol
70% is recommended.
When disinfecting the neck of the ampoule with an antiseptic, to avoid any interaction with the Pedea
solution, the ampoule must be completely dry before it is opened.

This medicinal product must not be mixed with other medicinal products except sodium chloride
9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml (5%) solution.

In order to avoid any substantial variation of pH due to the presence of acidic medicinal products that
could remain in the infusion line, the latter must be rinsed before and after administration of Pedea
with 1.5 to 2 ml of either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 50 mg/ml
(5%) solution.

22